North America Sleep Disorder Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2021 –2028 |
 Market Size (Base Year) |
USD 4,945.53 Million |
 Market Size (Forecast Year) |
USD 9,469.97 Million |
 CAGR |
% |
| Major Markets Players |
北美睡眠障碍治疗市场，按类型（失眠、睡眠呼吸暂停、不宁腿综合征 (RLS)、发作性睡病等）、治疗（药物治疗、机械治疗、下颌推进装置、舌下神经刺激器、手术等）、给药途径（口服、肠胃外等）、药物类型（品牌药和仿制药）、人群类型（儿童和成人）、最终用户（医院、专科诊所、家庭医疗保健、门诊手术中心等）、分销渠道（直接招标、医院药房、零售药房、网上药房等）、国家（美国、加拿大和墨西哥）划分的行业趋势和预测到 2028 年
市场分析与洞察：北美睡眠障碍治疗市场
北美睡眠障碍治疗市场预计将从 2020 年的 49.4553 亿美元增至 2028 年的 94.6997 亿美元，在 2021 年至 2028 年的预测期内的复合年增长率为 8.6%。由于全球睡眠呼吸暂停、失眠和嗜睡症等睡眠障碍的患病率增加，北美睡眠障碍治疗市场预计将增长。
睡眠障碍，例如睡眠呼吸暂停、发作性睡病或失眠症，是一种患者难以维持睡眠或入睡的疾病。这种疾病会导致精神、身体、社交和情绪功能紊乱。根据患者的症状，睡眠障碍可通过不同的治疗方法进行治疗。大多数睡眠呼吸暂停患者通过机械疗法进行治疗。抗抑郁药、大麻二酚、苯二氮卓类药物和兴奋剂等药物疗法可用于治疗失眠症、发作性睡病和不安腿综合征等。口腔内装置还用于通过创建气道通道来防止打鼾，以便为适当的气体交换创造空间。
预计市场的增长将受到诸多因素的推动，例如抑郁症和其他疾病发病率的上升、全球老年人口的增加、生活方式的改变、睡眠质量的下降，这些因素推动了睡眠障碍治疗市场的增长。FDA 批准的新药物和医疗器械的推出，用于治疗此类睡眠障碍，为睡眠障碍治疗市场的增长提供了机会。然而，主要睡眠障碍治疗药物的专利到期或专利悬崖以及与这些药物相关的副作用，限制了睡眠障碍治疗市场的增长。
The sleep disorder treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
North America Sleep Disorder Treatment Market Scope and Market Size
North America sleep disorder treatment market is segmented on the basis of type, treatment, route of administration, drugs type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the sleep disorder treatment market is segmented into insomnia, sleep apnea, restless legs syndrome (RLS), narcolepsy and others. In 2021, insomnia segment is dominating the market because of the growing awareness about the condition, more and more people are adopting the treatment options.
- On the basis of treatment, the sleep disorder treatment market is segmented into pharmacological therapy, mechanical therapy, mandibular advancement devices, hypoglossal nerve stimulator, surgery and others. In 2021, pharmacological therapy segment is dominating the market due to increased pipeline products for the treatment of sleep disorders by key market players.
- On the basis of route of administration, the sleep disorder treatment market is segmented into oral, parenteral and others. In 2021, oral segment is dominating the market due to the economical and safe form of administration leading to increased uptake by the suffered patients.
- On the basis of drugs type, the sleep disorder treatment market is segmented into branded and generics. In 2021, generics segment is dominating the market because of the economical nature and easy availability of the generics drugs for the treatment of sleep disorder.
- On the basis of population type, the sleep disorder treatment market is segmented into children and adults. In 2021, adults segment is dominating the market due to availability of the U.S. FDA approved pharmacological therapies for the treatment of sleep disorder in adults.
- On the basis of end user, the sleep disorder treatment market is segmented into hospitals, specialty clinics, home healthcare, ambulatory surgical center and others. In 2021, hospitals segment is dominating the market as hospitals are the prime location visited by patients for any procedure or surgery.
- 根据分销渠道，睡眠障碍治疗市场分为直接招标、医院药房、零售药房、网上药房和其他。2021 年，直接招标领域占据市场主导地位，因为大多数机构都通过直接招标采购药品，因此直接招标满足了医生和患者的需求。
睡眠障碍治疗市场国家层面分析
对睡眠障碍治疗市场进行分析，并按国家、类型、治疗、给药途径、药物类型、人口类型、最终用户和分销渠道提供市场规模信息。
睡眠障碍治疗市场报告涉及的国家包括美国、加拿大和墨西哥。
由于睡眠障碍在人口中越来越普遍，美国预计将主导市场。由于公司的产品组合不断增加，加拿大预计将实现增长。墨西哥预计将实现增长，因为它是一个新兴市场，市场参与者更加注重提供不同的产品。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
制造商推出的新产品为睡眠障碍治疗市场参与者创造了新的机会
睡眠障碍治疗市场还为您提供有关每个国家睡眠障碍治疗行业增长情况的详细市场分析，包括睡眠障碍治疗市场的销售、睡眠障碍治疗市场发展的影响以及监管环境的变化及其对睡眠障碍治疗市场的支持。数据涵盖 2010 年至 2018 年的历史时期。
竞争格局和睡眠障碍治疗市场份额分析
睡眠障碍治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对睡眠障碍治疗市场的关注有关。
睡眠障碍治疗市场的一些主要参与者包括 Jazz Pharmaceuticals, Inc.、Pfizer Inc.、Viatris Inc.、Arbor Pharmaceuticals、Aurobindo Pharma USA（Aurobindo Pharma 的子公司）、sanofi-aventis US LLC（Sanofi 的子公司）、Hikma Pharmaceuticals PLC、Amneal Pharmaceuticals LLC、Lupin Pharmaceuticals, Inc.（Lupin 的子公司）、Taj Pharmaceuticals Limited、Eli Lilly and Company、Mallinckrodt、Alembic Pharmaceuticals Limited、Apotex Inc.、Dr. Reddy's Laboratories Ltd.、Teva Pharmaceuticals USA, Inc.（Teva Pharmaceutical Industries Ltd. 的子公司）、Taro Pharmaceutical Industries Ltd.、Koninklijke Philips NV、DeVilbiss Healthcare LLC、ResMed、SomnoMed、Oventus 和 BMC Medical Co. 等。
全球各地的公司也发起了许多产品的发布和协议，这也加速了睡眠障碍治疗市场的发展。
例如，
- 2020 年 7 月，Jazz Pharmaceuticals plc 宣布其药物 Xyway 获得 FDA 批准，用于治疗 15 岁以上发作性睡病患者的猝倒症和白天过度嗜睡症。该公司的这款新型睡眠障碍治疗药物获得美国 FDA 批准，增加了市场对其药物的需求和销售，从而增加了未来的收入。
- 2016 年 6 月，Mylan NV 推出了 Nuvigil 药物的仿制药，名为阿莫达非尼片，用于治疗阻塞性睡眠呼吸暂停、发作性睡病或轮班工作障碍引起的过度嗜睡的成年人的觉醒。该公司在美国市场推出的这款新药增加了市场需求和销量，从而推动未来销量的增长。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: REGULATIONS
6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF SLEEPING DISORDERS
7.1.2 RISE IN THE GERIATRIC POPULATION
7.1.3 INCREASE IN MENTAL STRESS DUE TO HECTIC LIFE & UNHEALTHY HABITS
7.1.4 LARGE POOL OF UNDIAGNOSED SLEEP APNEA PATIENTS
7.1.5 PRESENCE OF POTENTIAL CLINICAL PIPELINE CANDIDATES
7.2 RESTRAINTS
7.2.1 SIDE EFFECTS ASSOCIATED WITH THESE DRUGS
7.2.2 PATENT EXPIRATION OF MAJOR SLEEP DISORDER TREATMENT DRUGS
7.2.3 EMERGENCE OF GENERICS
7.3 OPPORTUNITIES
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN THE SLEEP AIDS IN THE U.S.
7.3.2 INCREASING USAGE OF SOCIAL MEDIA AND GROWING ADDICTION OF GADGETS SUCH AS SMARTPHONES AND LAPTOPS
7.3.3 GROWING AWARENESS ABOUT TARGET DISEASE
7.4 CHALLENGES
7.4.1 HIGH COST OF DIAGNOSIS & TREATMENT FOR SLEEPING DISORDER
7.4.2 STRINGENT REGULATORY LANDSCAPE
7.4.3 POTENTIAL ILL-EFFECTS DUE TO DRUG ABUSE
8 IMPACT OF COVID-19 ON NORTH AMERICA SLEEP DISORDER TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.5 CONCLUSION
9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 INSOMNIA
9.2.1 INSOMNIA
9.2.2 CHILD INSOMNIA
9.2.3 OTHERS
9.3 SLEEP APNEA
9.3.1 OBSTRUCTIVE SLEEP APNEA
9.3.2 CENTRAL SLEEP APNEA
9.3.3 SNORING
9.3.4 INFANT SLEEP APNEA
9.3.5 OTHERS
9.4 RESTLESS LEGS SYNDROME (RLS)
9.5 NARCOLEPSY
9.5.1 TYPE 1
9.5.2 TYPE 2
10 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 PHARMACOLOGICAL THERAPY
10.2.1 CANNABIDIOL
10.2.2 ANTI-PARKINSONIAN DRUGS (DOPAMINE AGONISTS)
10.2.3 BENZODIAZEPINES
10.2.4 NON-BENZODIAZEPINE
10.2.5 MELATONIN RECEPTOR STIMULATOR
10.2.6 STIMULANTS
10.2.7 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) OR SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
10.2.8 TRICYCLIC ANTIDEPRESSANTS
10.2.9 SODIUM OXYBATE (XYREM)
10.2.10 OTHERS
10.3 MECHANICAL THERAPY
10.3.1 CPAP (CONTINUOUS POSITIVE AIRWAY PRESSURE)
10.3.2 BI-LEVEL PAP
10.3.3 AUTO CPAP OR AUTO BI-LEVEL PAP
10.3.4 ADAPTIVE SERVO-VENTILATION (ASV)
10.4 MANDIBULAR ADVANCEMENT DEVICES
10.5 HYPOGLOSSAL NERVE STIMULATOR
10.6 SURGERY
10.6.1 SOMNOPLASTY
10.6.2 TONSILLECTOMY
10.6.3 NASAL SURGERY
10.6.4 OTHERS
10.7 OTHERS
11 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 PILLS
11.2.3 OTHERS
11.3 PARENTERAL
11.4 OTHERS
12 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
12.3.1 XYREM
12.3.2 EFFEXOR XR
12.3.3 AMBIEN
12.3.4 PRISTIQ
12.3.5 ZENZEDI
12.3.6 VYVANSE
12.3.7 OTHERS
13 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE
13.1 OVERVIEW
13.2 ADULT
13.3 CHILDREN
14 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 AMBULATORY SURGICAL CENTER
14.6 OTHERS
15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACY
15.4 RETAIL PHARMACY
15.5 ONLINE PHARMACY
15.6 OTHERS
16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 JAZZ PHARMACEUTICALS, INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENT
19.3 ELI LILLY AND COMPANY
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 VIATRIS INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 RESMED
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 MALLINCKRODT
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 KONINKLIJKE PHILIPS N.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ALEMBIC PHARMACEUTICALS LIMITED
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 AMNEAL PHARMACEUTICALS LLC
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 APOTEX INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 ARBOR PHARMACEUTICALS
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 BMC MEDICAL CO.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 DEVILBISS HEALTHCARE LLC
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.15 DR. REDDY’S LABORATORIES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 HIKMA PHARMACEUTICALS PLC
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 OVENTUS
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI)
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SOMNOMED
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 TAJ PHARMACEUTICALS LIMITED
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENT
19.22 TARO PHARMACEUTICAL INDUSTRIES LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENT
19.23 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS
TABLE 2 GENERIC DRUGS FOR SLEEP DISORDER TREATMENT
TABLE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 6 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 8 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 9 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 10 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 11 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 12 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 13 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 14 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 15 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 U.S. SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 U.S. INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 36 U.S. SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)
TABLE 37 U.S. NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2019-2028 (USD MILLION)
TABLE 38 U.S. SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 39 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT , 2019-2028 (USD MILLION)
TABLE 40 U.S. MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 41 U.S. SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 42 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 43 U.S. ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 44 U.S. PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 45 U.S. BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 46 U.S. SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 47 U.S. SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 48 U.S. SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 49 CANADA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 CANADA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 CANADA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 CANADA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)
TABLE 53 CANADA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 54 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 55 CANADA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2019-2028 (USD MILLION)
TABLE 56 CANADA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 57 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 58 CANADA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 59 CANADA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 60 CANADA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 61 CANADA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 62 CANADA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 CANADA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 MEXICO INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 MEXICO SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 MEXICO NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, 2019-2028 (USD MILLION)
TABLE 68 MEXICO SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 69 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 70 MEXICO MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 71 MEXICO SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2019-2028 (USD MILLION)
TABLE 72 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 73 MEXICO ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 74 MEXICO PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 75 MEXICO BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 76 MEXICO SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 77 MEXICO SLEEP DISORDER TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 MEXICO SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 10 RISING PREVALENCE OF SLEEPING DISORDERS IS EXPECTED TO DRIVE THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 INSOMNIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SLEEP DISORDER TREATMENT MARKET IN 2021 & 2028
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA SLEEP DISORDER TREATMENT MARKET
FIGURE 13 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 14 PROPORTION OF AMERICAN TEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 15 PROPORTION OF AMERICAN TEENS (13- TO 18- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 16 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020
FIGURE 17 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 19 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020
FIGURE 21 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020-2028 (USD MILLION)
FIGURE 22 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, CAGR (2020-2028)
FIGURE 23 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 25 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 26 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 27 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020
FIGURE 29 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020-2028 (USD MILLION)
FIGURE 30 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, CAGR (2020-2028)
FIGURE 31 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 32 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020
FIGURE 33 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 34 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, CAGR (2020-2028)
FIGURE 35 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 36 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020
FIGURE 37 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 38 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 39 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 42 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 43 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 45 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 46 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: BY TYPE (2020-2028)
FIGURE 49 NORTH AMERICA SLEEP DISORDER TREATMENT MARKET: COMPANY SHARE 2020 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
